Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

The downregulation of putative anticancer target BORIS/CTCFL in an addicted myeloid cancer cell line modulates the expression of multiple protein coding and ncRNA genes.

Teplyakov E, Wu Q, Liu J, Pugacheva EM, Loukinov D, Boukaba A, Lobanenkov V, Strunnikov A.

Oncotarget. 2017 Sep 2;8(43):73448-73468. doi: 10.18632/oncotarget.20627. eCollection 2017 Sep 26.

2.

Discovering a binary CTCF code with a little help from BORIS.

Lobanenkov VV, Zentner GE.

Nucleus. 2018 Jan 1;9(1):33-41. doi: 10.1080/19491034.2017.1394536. Epub 2017 Dec 5.

PMID:
29077515
3.

Corrigendum: Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells.

Rivero-Hinojosa S, Kang S, Lobanenkov VV, Zentner GE.

Sci Rep. 2017 Aug 4;7:46891. doi: 10.1038/srep46891.

4.

Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells.

Rivero-Hinojosa S, Kang S, Lobanenkov VV, Zentner GE.

Sci Rep. 2017 Feb 1;7:41279. doi: 10.1038/srep41279. Erratum in: Sci Rep. 2017 Aug 04;7:46891.

5.

The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements.

Pugacheva EM, Teplyakov E, Wu Q, Li J, Chen C, Meng C, Liu J, Robinson S, Loukinov D, Boukaba A, Hutchins AP, Lobanenkov V, Strunnikov A.

Epigenetics Chromatin. 2016 Aug 31;9(1):35. doi: 10.1186/s13072-016-0084-2. eCollection 2016.

6.

Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.

Pugacheva EM, Rivero-Hinojosa S, Espinoza CA, Méndez-Catalá CF, Kang S, Suzuki T, Kosaka-Suzuki N, Robinson S, Nagarajan V, Ye Z, Boukaba A, Rasko JE, Strunnikov AV, Loukinov D, Ren B, Lobanenkov VV.

Genome Biol. 2015 Aug 14;16:161. doi: 10.1186/s13059-015-0736-8.

7.

Chromatin architecture reorganization during stem cell differentiation.

Dixon JR, Jung I, Selvaraj S, Shen Y, Antosiewicz-Bourget JE, Lee AY, Ye Z, Kim A, Rajagopal N, Xie W, Diao Y, Liang J, Zhao H, Lobanenkov VV, Ecker JR, Thomson JA, Ren B.

Nature. 2015 Feb 19;518(7539):331-6. doi: 10.1038/nature14222.

8.

Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.

Schwarzenbach H, Eichelser C, Steinbach B, Tadewaldt J, Pantel K, Lobanenkov V, Loukinov D.

BMC Cancer. 2014 Nov 3;14:796. doi: 10.1186/1471-2407-14-796.

9.

CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer.

Kemp CJ, Moore JM, Moser R, Bernard B, Teater M, Smith LE, Rabaia NA, Gurley KE, Guinney J, Busch SE, Shaknovich R, Lobanenkov VV, Liggitt D, Shmulevich I, Melnick A, Filippova GN.

Cell Rep. 2014 May 22;7(4):1020-9. doi: 10.1016/j.celrep.2014.04.004. Epub 2014 May 1.

10.

A novel mechanism for CTCF in the epigenetic regulation of Bax in breast cancer cells.

Méndez-Catalá CF, Gretton S, Vostrov A, Pugacheva E, Farrar D, Ito Y, Docquier F, Kita GX, Murrell A, Lobanenkov V, Klenova E.

Neoplasia. 2013 Aug;15(8):898-912.

11.

A genome-wide map of CTCF multivalency redefines the CTCF code.

Nakahashi H, Kieffer Kwon KR, Resch W, Vian L, Dose M, Stavreva D, Hakim O, Pruett N, Nelson S, Yamane A, Qian J, Dubois W, Welsh S, Phair RD, Pugh BF, Lobanenkov V, Hager GL, Casellas R.

Cell Rep. 2013 May 30;3(5):1678-1689. doi: 10.1016/j.celrep.2013.04.024. Epub 2013 May 23.

12.

A map of the cis-regulatory sequences in the mouse genome.

Shen Y, Yue F, McCleary DF, Ye Z, Edsall L, Kuan S, Wagner U, Dixon J, Lee L, Lobanenkov VV, Ren B.

Nature. 2012 Aug 2;488(7409):116-20. doi: 10.1038/nature11243.

13.

Loss of maternal CTCF is associated with peri-implantation lethality of Ctcf null embryos.

Moore JM, Rabaia NA, Smith LE, Fagerlie S, Gurley K, Loukinov D, Disteche CM, Collins SJ, Kemp CJ, Lobanenkov VV, Filippova GN.

PLoS One. 2012;7(4):e34915. doi: 10.1371/journal.pone.0034915. Epub 2012 Apr 20.

15.

Dynamic chromatin states in human ES cells reveal potential regulatory sequences and genes involved in pluripotency.

Hawkins RD, Hon GC, Yang C, Antosiewicz-Bourget JE, Lee LK, Ngo QM, Klugman S, Ching KA, Edsall LE, Ye Z, Kuan S, Yu P, Liu H, Zhang X, Green RD, Lobanenkov VV, Stewart R, Thomson JA, Ren B.

Cell Res. 2011 Oct;21(10):1393-409. doi: 10.1038/cr.2011.146. Epub 2011 Aug 30.

16.

Transcription factor BORIS (Brother of the Regulator of Imprinted Sites) directly induces expression of a cancer-testis antigen, TSP50, through regulated binding of BORIS to the promoter.

Kosaka-Suzuki N, Suzuki T, Pugacheva EM, Vostrov AA, Morse HC 3rd, Loukinov D, Lobanenkov V.

J Biol Chem. 2011 Aug 5;286(31):27378-88. doi: 10.1074/jbc.M111.243576. Epub 2011 Jun 9.

17.

Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.

Mkrtichyan M, Ghochikyan A, Davtyan H, Movsesyan N, Loukinov D, Lobanenkov V, Cribbs DH, Laust AK, Nelson EL, Agadjanyan MG.

Cell Immunol. 2011;270(2):188-97. doi: 10.1016/j.cellimm.2011.05.007. Epub 2011 May 12.

18.

The structural complexity of the human BORIS gene in gametogenesis and cancer.

Pugacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, Vostrov AA, Barsov E, Strunnikov AV, Morse HC 3rd, Loukinov D, Lobanenkov V.

PLoS One. 2010 Nov 8;5(11):e13872. doi: 10.1371/journal.pone.0013872.

19.

BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells.

Renaud S, Loukinov D, Alberti L, Vostrov A, Kwon YW, Bosman FT, Lobanenkov V, Benhattar J.

Nucleic Acids Res. 2011 Feb;39(3):862-73. doi: 10.1093/nar/gkq827. Epub 2010 Sep 28.

20.

Expression of a testis-specific form of Gal3st1 (CST), a gene essential for spermatogenesis, is regulated by the CTCF paralogous gene BORIS.

Suzuki T, Kosaka-Suzuki N, Pack S, Shin DM, Yoon J, Abdullaev Z, Pugacheva E, Morse HC 3rd, Loukinov D, Lobanenkov V.

Mol Cell Biol. 2010 May;30(10):2473-84. doi: 10.1128/MCB.01093-09. Epub 2010 Mar 15.

21.

Does CTCF mediate between nuclear organization and gene expression?

Ohlsson R, Lobanenkov V, Klenova E.

Bioessays. 2010 Jan;32(1):37-50. doi: 10.1002/bies.200900118. Review.

PMID:
20020479
22.

PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells.

Bougel S, Renaud S, Braunschweig R, Loukinov D, Morse HC 3rd, Bosman FT, Lobanenkov V, Benhattar J.

J Pathol. 2010 Jan;220(1):87-96. doi: 10.1002/path.2620.

23.

Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer.

Smith IM, Glazer CA, Mithani SK, Ochs MF, Sun W, Bhan S, Vostrov A, Abdullaev Z, Lobanenkov V, Gray A, Liu C, Chang SS, Ostrow KL, Westra WH, Begum S, Dhara M, Califano J.

PLoS One. 2009;4(3):e4961. doi: 10.1371/journal.pone.0004961. Epub 2009 Mar 23.

24.

Histone modifications at human enhancers reflect global cell-type-specific gene expression.

Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, Stuart RK, Ching CW, Ching KA, Antosiewicz-Bourget JE, Liu H, Zhang X, Green RD, Lobanenkov VV, Stewart R, Thomson JA, Crawford GE, Kellis M, Ren B.

Nature. 2009 May 7;459(7243):108-12. doi: 10.1038/nature07829. Epub 2009 Mar 18.

25.

Genome wide ChIP-chip analyses reveal important roles for CTCF in Drosophila genome organization.

Smith ST, Wickramasinghe P, Olson A, Loukinov D, Lin L, Deng J, Xiong Y, Rux J, Sachidanandam R, Sun H, Lobanenkov V, Zhou J.

Dev Biol. 2009 Apr 15;328(2):518-28. doi: 10.1016/j.ydbio.2008.12.039. Epub 2009 Jan 8.

26.

Human gamma-satellite DNA maintains open chromatin structure and protects a transgene from epigenetic silencing.

Kim JH, Ebersole T, Kouprina N, Noskov VN, Ohzeki J, Masumoto H, Mravinac B, Sullivan BA, Pavlicek A, Dovat S, Pack SD, Kwon YW, Flanagan PT, Loukinov D, Lobanenkov V, Larionov V.

Genome Res. 2009 Apr;19(4):533-44. doi: 10.1101/gr.086496.108. Epub 2009 Jan 13.

27.

Maternal depletion of CTCF reveals multiple functions during oocyte and preimplantation embryo development.

Wan LB, Pan H, Hannenhalli S, Cheng Y, Ma J, Fedoriw A, Lobanenkov V, Latham KE, Schultz RM, Bartolomei MS.

Development. 2008 Aug;135(16):2729-38. doi: 10.1242/dev.024539. Epub 2008 Jul 9.

28.

BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.

D'Arcy V, Pore N, Docquier F, Abdullaev ZK, Chernukhin I, Kita GX, Rai S, Smart M, Farrar D, Pack S, Lobanenkov V, Klenova E.

Br J Cancer. 2008 Feb 12;98(3):571-9. doi: 10.1038/sj.bjc.6604181. Epub 2008 Jan 15. Erratum in: Br J Cancer. 2008 Feb 12;98(3):676.

29.

DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice.

Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG.

Gene Ther. 2008 Jan;15(1):61-4. Epub 2007 Nov 1.

30.

Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.

Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, Benhattar J, Lobanenkov V.

Nucleic Acids Res. 2007;35(21):7372-88. Epub 2007 Oct 25.

31.

Evolutionary diversification of SPANX-N sperm protein gene structure and expression.

Kouprina N, Noskov VN, Pavlicek A, Collins NK, Schoppee Bortz PD, Ottolenghi C, Loukinov D, Goldsmith P, Risinger JI, Kim JH, Westbrook VA, Solomon G, Sounders H, Herr JC, Jurka J, Lobanenkov V, Schlessinger D, Larionov V.

PLoS One. 2007 Apr 4;2(4):e359.

32.

Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome.

Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI, Green RD, Zhang MQ, Lobanenkov VV, Ren B.

Cell. 2007 Mar 23;128(6):1231-45.

33.

Interspecies comparative genomic hybridization (I-CGH): a new twist to study animal tumor models.

Jaikumar S, Zhuang Z, Mannan P, Vortmeyer AO, Furuta M, Dickerman R, Bedanova J, Lonser RR, Walbridge S, Weil RJ, Lobanenkov VV, Oldfield EH, Pack SD.

Cell Cycle. 2007 Apr 1;6(7):836-42. Epub 2007 Apr 25.

PMID:
17377495
34.

Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression.

Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK, Berchuck A, Lobanenkov V, Barrett JC.

Clin Cancer Res. 2007 Mar 15;13(6):1713-9.

35.

Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene.

Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman FT, Lobanenkov V, Benhattar J.

Nucleic Acids Res. 2007;35(4):1245-56. Epub 2007 Jan 31.

36.

Allele-specific binding of CTCF to the multipartite imprinting control region KvDMR1.

Fitzpatrick GV, Pugacheva EM, Shin JY, Abdullaev Z, Yang Y, Khatod K, Lobanenkov VV, Higgins MJ.

Mol Cell Biol. 2007 Apr;27(7):2636-47. Epub 2007 Jan 22.

37.

A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis.

Hancock AL, Brown KW, Moorwood K, Moon H, Holmgren C, Mardikar SH, Dallosso AR, Klenova E, Loukinov D, Ohlsson R, Lobanenkov VV, Malik K.

Hum Mol Genet. 2007 Feb 1;16(3):343-54. Epub 2007 Jan 8.

PMID:
17210670
38.

CTCF interacts with and recruits the largest subunit of RNA polymerase II to CTCF target sites genome-wide.

Chernukhin I, Shamsuddin S, Kang SY, Bergström R, Kwon YW, Yu W, Whitehead J, Mukhopadhyay R, Docquier F, Farrar D, Morrison I, Vigneron M, Wu SY, Chiang CM, Loukinov D, Lobanenkov V, Ohlsson R, Klenova E.

Mol Cell Biol. 2007 Mar;27(5):1631-48. Epub 2007 Jan 8.

39.

Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.

Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG.

J Immunol. 2007 Jan 1;178(1):566-73.

40.

The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis.

D'Arcy V, Abdullaev ZK, Pore N, Docquier F, Torrano V, Chernukhin I, Smart M, Farrar D, Metodiev M, Fernandez N, Richard C, Delgado MD, Lobanenkov V, Klenova E.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5978-86.

41.

CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2.

Kurukuti S, Tiwari VK, Tavoosidana G, Pugacheva E, Murrell A, Zhao Z, Lobanenkov V, Reik W, Ohlsson R.

Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10684-9. Epub 2006 Jun 30.

42.

Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.

Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG.

J Cell Biochem. 2006 Aug 1;98(5):1037-43.

PMID:
16741971
43.

Cloning and characterization of zebrafish CTCF: Developmental expression patterns, regulation of the promoter region, and evolutionary aspects of gene organization.

Pugacheva EM, Kwon YW, Hukriede NA, Pack S, Flanagan PT, Ahn JC, Park JA, Choi KS, Kim KW, Loukinov D, Dawid IB, Lobanenkov VV.

Gene. 2006 Jun 21;375:26-36. Epub 2006 May 2.

PMID:
16647825
44.

CTCF binds the proximal exonic region of hTERT and inhibits its transcription.

Renaud S, Loukinov D, Bosman FT, Lobanenkov V, Benhattar J.

Nucleic Acids Res. 2005 Dec 2;33(21):6850-60. Print 2005.

45.

Rasgrf1 imprinting is regulated by a CTCF-dependent methylation-sensitive enhancer blocker.

Yoon B, Herman H, Hu B, Park YJ, Lindroth A, Bell A, West AG, Chang Y, Stablewski A, Piel JC, Loukinov DI, Lobanenkov VV, Soloway PD.

Mol Cell Biol. 2005 Dec;25(24):11184-90.

46.

Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.

Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS.

Cancer Res. 2005 Sep 1;65(17):7763-74.

47.

Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.

Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H 3rd, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV.

Cancer Res. 2005 Sep 1;65(17):7751-62.

48.

Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis.

Docquier F, Farrar D, D'Arcy V, Chernukhin I, Robinson AF, Loukinov D, Vatolin S, Pack S, Mackay A, Harris RA, Dorricott H, O'Hare MJ, Lobanenkov V, Klenova E.

Cancer Res. 2005 Jun 15;65(12):5112-22.

49.

Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.

Mummert SK, Lobanenkov VA, Feinberg AP.

Genes Chromosomes Cancer. 2005 Jun;43(2):155-61.

PMID:
15761865
50.

Familial cases of point mutations in the XIST promoter reveal a correlation between CTCF binding and pre-emptive choices of X chromosome inactivation.

Pugacheva EM, Tiwari VK, Abdullaev Z, Vostrov AA, Flanagan PT, Quitschke WW, Loukinov DI, Ohlsson R, Lobanenkov VV.

Hum Mol Genet. 2005 Apr 1;14(7):953-65. Epub 2005 Feb 24.

PMID:
15731119

Supplemental Content

Loading ...
Support Center